IPP Bureau
U.S. FDA approves Repatha for paediatric patients aged 10 years and older
By IPP Bureau - September 27, 2021
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
Cadila Healthcare signs agreement with Shilpa Medicare for production of ZyCoV-D
By IPP Bureau - September 26, 2021
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
By IPP Bureau - September 26, 2021
The company does not expect the outcome of this inspection to impact its plans
SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
By IPP Bureau - September 26, 2021
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
MedleyMed enters the U.S. market with a suite of digital health solutions
By IPP Bureau - September 26, 2021
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
AstraZeneca Pharma India receives permission for paediatric drug
By IPP Bureau - September 26, 2021
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Novavax and Serum seek WHO approval for Covid-19 vaccine
By IPP Bureau - September 24, 2021
It is a recombinant nanoparticle protein-based vaccine
Surgery added to Practo’s offerings
By IPP Bureau - September 24, 2021
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
Zydus Cadila receives final approval for Apremilast
By IPP Bureau - September 24, 2021
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
AstraZeneca to collaborate with VaxEquity for self-amplifying RNA therapy
By IPP Bureau - September 24, 2021
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Lancet publishes NanoFlu vaccine Phase 3 trial results
By IPP Bureau - September 24, 2021
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Health Sensei wins Stanford Seed Spark competition
By IPP Bureau - September 24, 2021
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
Amaris Clinicals clears U.S. FDA audit
By IPP Bureau - September 24, 2021
The company is the Clinical Research Organisation of Caplin Point Laboratories
Aurobindo subsidiary submits MAA for oncology biosimilar
By IPP Bureau - September 23, 2021
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Roche launches three respiratory test panels on Cobas 6800/8800 Systems in CE markets
By IPP Bureau - September 23, 2021
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
